United States: Shifting Paradigms?: The Potential Impact Of MACRA On What Constitutes Fair Market Value And Commercial Reasonableness In Physician Transactions

Last Updated: March 1 2017

Article by William B. Eck, Seyfarth Shaw LLP, Washington, DC
Andrea M. Ferrari, JD, MPH, HealthCare Appraisers Inc, Delray Beach, FL
Tizgel K.S. High, LifePoint Health, Brentwood, TN
David S. Szabo, Locke Lord LLP, Boston, MA

This article is brought to you by the Fair Market Value Affinity Group of the Hospitals and Health Systems Practice Group.

On November 4, 2016, the Centers for Medicare & Medicaid Services (CMS) published its "final rule with comment period" implementing the Medicare Access and CHIP Reauthorization Act (MACRA).1 This highly-anticipated final rule set forth new details, conditions, and timelines for the physician payment changes that will follow from MACRA, which repealed and replaced the unpopular sustainable growth rate (SGR) formula for calculating annual Medicare payment changes for physicians.

MACRA replaced the SGR formula with the Medicare Quality Payment Program or "QPP." The QPP provides two options for future clinician payments from Medicare: (1) participation in the Merit-Based Incentive Payment System or "MIPS"; or (2) participation in one or more Alternative Payment Models or "APMs."2 Both options will transition clinicians away from traditional "volume based" payment criteria to newer "value based" payment criteria. The likely result is that MACRA will transform the norms for provider compensation throughout the marketplace, given that Medicare payment practices typically set the standard for general market practices.

More often than not, the ability to demonstrate that health care provider compensation is fair market value (FMV) and commercially reasonable is the lynchpin for a regulatory-compliant transaction or arrangement. As recent court cases such as Tuomey3 have illustrated, compensation that does not meet the "FMV" and "commercially reasonable" standards may put providers at risk for financially ruinous consequences. With this in mind, and with recognition that FMV and commercial reasonableness are difficult to appropriately evaluate without an understanding of the market forces that may influence them, this article will discuss how MACRA may transform market forces and economics in the coming years, and how that transformation may affect the questions and answers about FMV and commercial reasonableness of physician compensation.

Overview of MIPS

MIPS requires that clinicians participating in Medicare be subject to payment adjustments (positive or negative) based on performance in four categories of measures: (1) quality, (2) advancing care information, (3) clinical practice improvement activities, and (4) cost. Clinicians subject to MIPs include physicians and other care providers such as physician assistants, nurse practitioners, clinical nurse specialists, and certified registered nurse anesthetists.4 MIPS is designed to incentivize quality and value improvements in health care delivery while maintaining Medicare budget neutrality and thus there will be both "winners" and "losers" under MIPS.5 A certain number of eligible clinicians will be subject to reimbursement reductions in order for others to achieve reimbursement enhancements. Since even those clinicians who are subject to reimbursement reductions may have made investments in new technology or infrastructure in order to have a hope of achieving the reimbursement enhancements, there is some risk inherent in participating in MIPS.

There is a two-year lag between the period during which MIPS performance data is collected (measurement period) and the period during which corresponding payment adjustments are made (payment period).6 A physician who fails to report data or whose reports suggest "below average performance" during a measurement period will suffer the consequences two years later. The final rule relaxed the reporting requirements and performance standards for the 2017 measurement period, but for 2018 and beyond, the standards will be more stringent, which suggests that payment reductions will be looming for more physicians in 2020 and later years.

Overview of APMs

Eligible clinicians may avoid participation in MIPS by participating in qualifying APMs. Qualifying APMs must meet specific criteria related to: (1) use of certified electronic health record technology (CEHRT),7 (2) payments conditioned on achievement of quality criteria that are comparable to the quality criteria in the quality performance category of MIPS, and (3) entity risk-bearing for poor performance and monetary losses.8 Providers who participate in qualifying APMs (Advanced APMs) may receive a 5% annual incentive bonus beginning in 2019, with potentially higher incentive payments later.9 However, achievement of these bonuses may require some upfront expenditure – for example, expenditure for new IT, analytics software and/or for enhanced care management processes. One might reasonably speculate that the inevitable need for upfront investment may blunt the net economic benefit of the available incentive payments, at least initially. Moreover, participation in Advanced APMs inherently comes with downside risk: payments must be subject to reduction for failure to achieve benchmark standards, and more than a nominal portion of the risk of loss must be borne by participating clinicians in order for the clinicians to qualify for APM participation as an alternative to MIPS.10

Significantly, a physician could be affiliated with an entity that is set up to be an Advanced APM, but not experience sufficient volume in the alternative payment plan to gain exemption from MIPS. Thus, physicians who seek to participate in Advanced APMs will ignore MIPS performance at their own peril.11

APMs Under the Final Rule:

Medicare Advanced APMs and other payer Advanced APMs must, in general:
  1. Use electronic health records;
  2. Pay for professional services based on quality measures similar to MIPS; and
  3. Require that APM participants, including physicians, bear risk of more than a nominal amount, or be a Medicare or Medicaid medical home.
CMS Announced Advanced APMs specifically include:
  1. Comprehensive Primary Care Plus, a national model under the Affordable Care Act;
  2. Next generation ACOs;
  3. Medicare Shared Savings Programs, Tracks 2 and 3;
  4. Certain Oncology Care Models with two-sided risk; and
  5. Certain large scale comprehensive ESRD care models.

Impact on Practice Costs

Initially, physician practice expenses may increase under MACRA due to the need to invest in the infrastructure necessary to achieve the upside benefits of MIPS and APMs. Larger practices may have the most substantial expenditures, but may also have the benefit of being able to spread their costs over a greater number of revenue generators. Smaller practices with more limited purchasing power, including sole providers and small physician-owned groups, may find themselves without access to adequate infrastructure, particularly with respect to IT, and some fear that they may be at a disadvantage in responding to the reimbursement changes. Experts indicate that some of the most expensive but also important investments to prepare for MACRA may be: (1) electronic health records and other tools to permit tracking, aggregation, and analysis of data; and (2) support systems to identify and plan necessary changes in practice patterns. The need for these investments may have substantial impact on the economics of provider service delivery, and consequently, may force changes to the prevailing models of care delivery, as we discuss further below.

Impact on Sources and Amount of Physician Compensation

Medicare is currently a major source of payment for certain types of physician services, including services related to end stage renal disease (nephrology), joint replacement (orthopedics), ophthalmology, and heart disease (cardiology), to name a few. The implementation of MACRA may significantly affect compensation trends for physicians who perform these services. Also, if other payers in the marketplace follow the lead of the Medicare program to model their own payment policies (as often happens), then the effects of MACRA may be quite dramatic and affect providers of nearly all specialties.

The potential for dramatic changes in reimbursement poses some risk for hospitals and health systems that employ physicians. Recent False Claims Act litigation has focused attention on hospital losses as an indicator of inappropriate physician compensation. Some qui tam plaintiffs have successfully argued that such losses are evidence of non-FMV, unreasonable compensation that fails the requirements of the Stark Law, and/or implies violation of the Anti-kickback Statute.12 If current litigation and enforcement trends continue, hospital-affiliated employers may face substantial financial risk if their employed physicians fail to meet the required benchmarks for full reimbursement under MACRA but their employment compensation does not adjust accordingly. Fixed rates of compensation per work relative value unit (wRVU), which were once considered a fairly safe bet for regulatory-compliant physician employment models, have the potential in the future to become fraught with risk.

Impact on Practice Models and Clinical Integration

Physician practice models have evolved and transformed several times in recent decades. In the last five to six years, there has been a wave of provider consolidation, with large numbers of mergers and acquisitions and increasing physician employment by hospitals and health systems and their affiliated organizations. The implementation of MACRA may affect both the pace and direction of the consolidation trend. On the one hand, a desire for economies of scale related to the need for access to IT and other efficiency building infrastructure may increase the interest in consolidation among independent physicians, especially in markets with less favorable payer mix and high dependence on government payers such as Medicare.

On the other hand, the combined effects of increasing practice costs and difficulty projecting future revenue may have a chilling effect for would-be purchasers and managers of many physician practices, particularly in the current enforcement environment, in which the financial impact of transactions with poor economics might easily go from bad to disastrous. Our reference to "disastrous" financial impact is, in part, a reference to the risk of liability under the Stark Law, Anti-kickback Statute, and/or False Claims Act. If the FMV or commercial reasonableness of physician compensation comes into question, as may happen in the wake of a physician practice transaction or physician employment relationship that yields substantial and seemingly unjustified losses for the purchaser and employer, the consequences could be enormous. The difficulty in projecting future revenue arises from both (1) uncertainty about the state of the market given, for example, uncertainty about the potential for repeal and replacement of the Affordable Care Act; and (2) uncertainty about the performance of individual eligible providers under MIPs or their chosen APM. There are also antitrust enforcement concerns about some types of transactions.

The competing desires for economies of scale and mitigation of consolidation risk may increase interest and participation in clinically integrated networks (CINs) and accountable care organizations (ACOs). Participation in a CIN or ACO may allow providers to share and spread the cost of IT, analytics, and care management resources without transferring ownership or accountability for practice performance. However, participation in a CIN or ACO comes with its own set of financial questions, particularly for the hospitals, health systems, and affiliates that already employ physicians and may be the primary owner and funding source for a CIN's or ACO's operations. A CIN or ACO can be costly to establish and operate. As such, there is significant financial risk related to poor performance. Does this financial risk become a regulatory compliance risk if losses are not appropriately spread or accounted for in the CIN's or ACO's relationships with participating providers and/or in its revenue allocation and distribution plans? Is the risk allocation appropriate to allow the participating providers to qualify as APM participants under the MACRA final rule? Answers to such questions are intertwined with the answers to questions about what constitutes a commercially reasonable and FMV financial arrangement for a provider in the post-MACRA world.

What MACRA Might Mean for FMV and Commercial Reasonableness Determinations

The Importance of FMV and Commercially Reasonable Compensation

Various laws make "fair market value" and "commercial reasonableness" a legal focus of health care transactions and contracts.13 The law that typically receives the most attention is the federal Physician Self-Referral or Stark Law, a strict liability statute that, absent an exception, is violated when a physician or an immediate family member has a "financial relationship" with an entity (which may be an ownership, investment, or compensation relationship) and the physician makes a "referral" to the entity for the furnishing of any of a specified list of "designated health services"14 that are payable by Medicare. To avoid liability under the Stark Law, the financial relationship must meet all the requirements for one of an enumerated list of Stark Law exceptions. Many of the exceptions have a requirement that compensation be consistent with or not exceed FMV, and several have a requirement that the compensation arrangement be "commercially reasonable." Some of the enumerated exceptions do not contain the words "commercially reasonable" but nonetheless contain elements that suggest a need for reasonableness in the financial relationship. For example, the Stark Law exception for personal services arrangements has a requirement that "aggregate services contracted for do not exceed those that are reasonable and necessary for the legitimate business purposes of the arrangement(s)."15

Violations of the Stark Law give rise to liability for each claim submitted pursuant to a prohibited referral. Liability for violations can add up quickly and to astronomical amounts. Repeated or egregious violations may lead to debarment from Medicare and other health care payment programs. Also, the Stark Law is not the only reason to be concerned about whether compensation is FMV and commercially reasonable. There are several other anti-fraud and abuse laws that make FMV and commercially reasonable compensation an implicit imperative, even if not an explicit requirement. The potential liability for violations of these laws may be equally or more troublesome than liability under the Stark Law, particularly if the violations co-exist with violations of the Stark Law.

To read this article in full, please click here.

Footnotes

1 Medicare Access and CHIP (Children's Health Insurance Program) Reauthorization Act of 2015 (MACRA), P.L. No. 114-10 (Apr. 16, 2015). The final rule was posted to the CMS website on October 14, 2016 and was published in the Federal Register on November 4, 2016. See 81 Fed. Reg. 77008 (Nov. 4, 2016).

2 Id. at 77009.

3 See U.S. ex rel. Drakeford v. Tuomey Health System, Inc., No. 3:05-2858- MBS (D.S.C.), which was a qui tam relator's lawsuit brought under the federal False Claims Act. After nearly a decade of litigation, including two jury trials, Tuomey Health System was ordered to pay $237.5 million for violations of the Stark Law and federal False Claims Act. The verdict was upheld on appeal to the Fourth Circuit, and then settled for $72.4 million. At issue in Tuomey was the compensation paid in part-time physician employment arrangements that the government and relator (with an opinion of their expert) contended was not fair market value, not commercially reasonable, and took into account the volume and value of referrals from the physicians.

4 81 Fed. Reg. at 77039; see also, www.qualitypaymentprogram.CMS.gov.

5 81 Fed. Reg. at 77016 ("The final score will be used to determine whether a MIPS eligible clinician receives an upward MIPS payment adjustment, no MIPS payment adjustment, or a downward MIPS payment adjustment as appropriate. Upward MIPS payment adjustments may be scaled for budget neutrality, as required by MACRA.").

6 Id. at 77083; www.qualitypaymentprogram.CMS.gov.

7 Id. at 77019, 77408-9.

8 Id. at77406, 77408.

9 Id. at 77480.

10 Id. at 77422-3.

11 See CMS, The Quality Payment Program, https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-10-25.html (viewed Dec. 27, 2016).

12 See, e.g., U.S. ex rel. Drakeford v. Tuomey Health System, supra note 3.

13 The federal Physician Self-Referral (Stark) Law (42 U.S.C. § 1395nn), the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7(b)) and federal False Claims Act (31 U.S.C. § 3729) are generally regarded as the primary reasons for giving careful attention to the fair market value and commercial reasonableness of compensation paid in health care transactions. In addition to these potentially applicable laws, for entities that are not-for-profit and tax-exempt under section 501(c)(3) of the Internal Revenue Code, there is a need to avoid engaging in transactions that produce private inurement or excess private benefit, which is generally accomplished by ensuring that compensation paid in transactions is "reasonable." In a state in which local laws and regulations include counterparts to any the above-referenced federal law and regulations, state laws and regulations may be an additional reason to give consideration to compensation terms – including FMV and reasonableness.

14 DHS is defined in the Stark Law to include: (i) clinical laboratory services; (ii) physical therapy services; (iii) occupational therapy services; (iv) radiology services, including magnetic resonance imaging, computerized axial tomography scans and ultrasound services; (v) radiation therapy and supplies; (vi) durable medical equipment and supplies; (vii) parenteral and enteral nutrients, equipment and supplies; (viii) prosthetics, orthotics and prosthetic devices and supplies; (ix) home health services; (x) outpatient prescription drugs; (xi) inpatient and outpatient hospital services; and (xii) outpatient speech and language pathology services.

15 42 C.F.R. § 411.357(d).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions